Business
Vera Therapeutics to Participate at September Investor Conferences
BRISBANE, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing
About this update from Vera Therapeutics, Inc.
[{"type":"text","content":"BRISBANE, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will present and participate in one-on-one meetings at investor conferences being held in September. Investor Conference Details: Wells Fargo Healthcare ConferenceFormat: 1x1sDate: Thursday, September 5, 2024Location: Boston, MACantor Global Healthcare ConferenceFormat: Fireside Chat and 1x1sWebcast: https://wsw.com/webcast/cantor22/vera/2084634Date: Wednesday, September 18, 2024Time: 9:10am EDTLocation: New York, NY A replay of the webcast will be available for 90 days and can be accessed by visiting the “Investor Calendar” section of the Vera Therapeutics website. About VeraVera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera’s mission is to advance treatments that target the source of immunological diseases in order to change the standard of care for patients. Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger’s disease, and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. Vera retains all global developmental and commercial rights to atacicept and MAU868. For more information, please visit www.veratx.com. For more information, please contact: Investor Contact:Joyce AllaireLifeSci [email protected] Media Contact:Madelin Hawtin LifeSci [email protected] \nSource: Vera Therapeutics","length":5522,"tagName":"div"}]